Am J Perinatol 2016; 33(11): 1099-1103
DOI: 10.1055/s-0036-1586102
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Portal Vein Thrombosis in a Preterm Newborn with Mutation of the MTHFR and PAI-1 Genes and Sepsis by Candida parapsilosis

On behalf of the Study Group of Neonatal Infectious Diseases Affiliated to the Italian Society of Neonatology.
Mario Giuffrè
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
,
Clelia Lo Verso
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
,
Gregorio Serra
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
,
Giovanni Moceri
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
,
Marcello Cimador
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
,
Giovanni Corsello
1   Neonatology and Neonatal Intensive Care Unit, Department of Sciences for Health Promotion and Mother and Child Care, Palermo University, Palermo, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
07 September 2016 (online)

Abstract

Objective This report discusses the role of both congenital and acquired risk factors in the pathogenesis of portal vein thrombosis (PVT).

Study Design We describe the clinical management and treatment of PVT in a preterm newborn with a homozygous mutation of the methylenetetrahydrofolate reductase (MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes and sepsis by Candida parapsilosis.

Results Although literature data suggest a minor role of genetic factors in thrombophilia in the case of only one mutation, we hypothesize that combined thrombophilic genetic defects may have a cumulative effect and significantly increase the thrombotic risk.

Conclusion It could be appropriate to include more detailed analyses of procoagulant and fibrinolytic factors in the diagnostic workup of neonatal thrombosis, also through the investigation of genetic polymorphisms. The anticoagulant therapy and the removal of concurrent risk factors remain basic steps for the adequate management and prevention of complications.

 
  • References

  • 1 Heller C, Schobess R, Kurnik K. , et al; For the Childhood Thrombophilia Study Group. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. Br J Haematol 2000; 111 (02) 534-539
  • 2 Morag I, Epelman M, Daneman A. , et al. Portal vein thrombosis in the neonate: risk factors, course, and outcome. J Pediatr 2006; 148 (06) 735-739
  • 3 Nowak-Göttl U, Janssen V, Manner D, Kenet G. Venous thromboembolism in neonates and children—update 2013. Thromb Res 2013; 131 (Suppl. 01) S39-S41
  • 4 Williams S, Chan AK. Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med 2011; 16 (06) 329-339
  • 5 Bhat R, Monagle P. The preterm infant with thrombosis. Arch Dis Child Fetal Neonatal Ed 2012; 97 (06) F423-F428
  • 6 Bothur-Nowacka J, Czech-Kowalska J, Gruszfeld D. , et al. Complications of umbilical vein catherisation. Case Report. Pol J Radiol 2011; 76 (03) 70-73
  • 7 Park CK, Paes BA, Nagel K, Chan AK, Murthy P. ; Thrombosis and Hemostasis in Newborns (THiN) Group. Neonatal central venous catheter thrombosis: diagnosis, management and outcome. Blood Coagul Fibrinolysis 2014; 25 (02) 97-106
  • 8 Ferraù V, Ferro E, Barone C. , et al. Thrombophilia screening: clinical and genetic aspects. Ital J Genet Pediatr Immunol 2011; 1: 3
  • 9 Yumani DF, van den Dungen FA, van Weissenbruch MM. Incidence and risk factors for catheter-associated bloodstream infections in neonatal intensive care. Acta Paediatr 2013; 102 (07) e293-e298
  • 10 Manzoni P, Benjamin DK, Hope W. , et al. The management of Candida infections in preterm neonates and the role of micafungin. J Matern Fetal Neonatal Med 2011; 24 (Suppl. 02) 24-27
  • 11 de la Torre P, Reboli AC. Micafungin: an evidence-based review of its place in therapy. Core Evid 2014; 9: 27-39
  • 12 Chow BD, Linden JR, Bliss JM. Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting. Expert Rev Anti Infect Ther 2012; 10 (08) 935-946
  • 13 Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49 (02) 767-769
  • 14 Monagle P, Chalmers E, Chan A. , et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 887S-968S